Health

Developing

Pill with chemotherapy shows promise for advanced pancreatic cancer in Barcelona trial

· 1 source · Ireland edition

This story has no audio yet

A once-a-day pill, daraxonrasib, combined with chemotherapy has produced striking results for people with advanced pancreatic cancer in a clinical trial presented in Barcelona. The drug blocks the mutated KRAS gene, which signals cancer cells to grow. Dr Wungki Park of Memorial Sloan Kettering Cancer Centre in New York, who presented the findings, said that in about one in 12 patients the disease completely disappeared.

Tumours shrank or disappeared in 60.7% of patients, and stopped growing in 90.2% of the 61 patients studied over a typical follow-up of 18 months. Of the whole group, 76.6% were alive one year after treatment, against around 40% to 45% on chemotherapy alone. Tumours took an average of 12.8 months to return or grow again, and fewer than 5% stopped treatment.

Asked whether patients whose tumours disappeared were cured, Park said it was the closest to a cure. Dr Madina Kara of Pancreatic Cancer UK called it a small, initial study with encouraging results. Michelle Mitchell of Cancer Research UK said more trials are needed before the treatment can be assessed for NHS use.

Key points

  • A once-a-day pill, daraxonrasib, combined with chemotherapy has shown promise for advanced pancreatic cancer in a trial presented in Barcelona.
  • Tumours completely disappeared in about one in 12 patients, Dr Wungki Park of Memorial Sloan Kettering Cancer Centre said.
  • Of the whole group, 76.6% were alive one year after treatment, against around 40% to 45% on chemotherapy alone.
  • Tumours shrank or disappeared in 60.7% of patients, and fewer than 5% stopped treatment.
  • Cancer Research UK said more trials are needed before the treatment can be assessed for use on the NHS.

Coverage from

This story was put together automatically from the sources above. Open a source to read its original report. How nuze makes stories